Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8IXS2

UPID:
DRC2_HUMAN

ALTERNATIVE NAMES:
Coiled-coil domain-containing protein 65; Testis development protein NYD-SP28

ALTERNATIVE UPACC:
Q8IXS2; A6NJG5; B2RBE2; Q8N7G4; Q8NA91; Q96JA0

BACKGROUND:
The Dynein regulatory complex subunit 2, known for its alternative names Coiled-coil domain-containing protein 65 and Testis development protein NYD-SP28, is integral to ciliary and flagellar movement. It forms a central scaffold with DRC1 for the nexin-dynein regulatory complex (N-DRC), which is essential for microtubule sliding in motile axonemes and maintaining axoneme alignment.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in primary ciliary dyskinesia, specifically type 27, Dynein regulatory complex subunit 2 represents a key target for drug discovery. The disease's hallmark, including chronic respiratory infections and the potential for situs inversus, highlights the importance of this protein in developing new treatments. Exploring the functions of Dynein regulatory complex subunit 2 could lead to innovative therapeutic approaches for these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.